Studies of Elevated Parathyroid Activity

Launched by NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES (NIDDK) · Nov 3, 1999

Keywords

ClinConnect Summary

Observational: Patients with confirmed or suspected primary hyperparathyroidism or complications therefrom (such as postoperative hypoparathyroidism) will be admitted for diagnosis and treatment. The principal diagnostic components are calcium in serum and urine, parathyroid hormone in serum, and mutation tests on germline or tumor DNA. Patients with moderate to severe primary hyperparathyroidism will be treated. Treatment will be mainly by parathyroidectomy. Other options are medications or no intervention. Patients with a hyperparathyroid syndrome may be managed for their extraparathyroid...

Gender

ALL

Eligibility criteria

• INCLUSION CRITERIA:
• • Patients who have genetically confirmed MEN1 or clinical criteria of MEN1.
• • For females: Negative urine pregnancy test OR post-menopausal for at least 2 years OR patient has had a hysterectomy
• EXCLUSION CRITERIA:
• • Serious underlying medical conditions that restrict diagnostic testing or therapy such as renal failure or congestive cardiac failure
• • Patients unable or unwilling to give informed consent
• • Pregnant or lactating women: Pregnant women are excluded from this study because the effects of 68Ga-DOTATATE in pregnancy are not known. Because there is an unknown but potential risk for adverse events in nursing infants secondary to administration of 68Ga-DOTATATE in the mother, women who are breastfeeding are also excluded from this study
• • Patients that have recognized concurrent active infection
• • Patients with known hypersensitivity to carbidopa, or who are concurrently taking a nonselective monoamine oxidase (MAO) inhibitor..